Pulmonary Hypertension News and Research RSS Feed - Pulmonary Hypertension News and Research

Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
ESC releases novel position paper on tackling cardiotoxicity of anticancer treatments

ESC releases novel position paper on tackling cardiotoxicity of anticancer treatments

The European Society of Cardiology has launched a novel position paper, under the auspices of its Committee for Practice Guidelines, on tackling the cardiac toxicity of anticancer therapies. The cardio-oncology paper is published online today in European Heart Journal and on the ESC Website. [More]
Experts develop new genomic testing method for pulmonary hypertension caused by genetic mutation

Experts develop new genomic testing method for pulmonary hypertension caused by genetic mutation

Pulmonology and genetics experts from two Utah healthcare organizations have collaboratively developed a new diagnostic genomic testing method for a rare form of pulmonary hypertension caused by a genetic mutation they discovered three years ago. [More]
Disordered airway microbiome at birth may be linked to severe neonatal lung disease

Disordered airway microbiome at birth may be linked to severe neonatal lung disease

In contrast to the general belief that the airways of an infant are sterile until after birth, University of Alabama at Birmingham researchers and colleagues have found that the infant airway is already colonized with bacteria or bacterial DNA when a baby is born -- and this is true for infants born as early as 24 weeks gestation. [More]
Testing lung health online: an interview with Professor Stephen Holgate

Testing lung health online: an interview with Professor Stephen Holgate

In our latest report – The Battle for Breath – the impact of lung disease in the UK, figures suggest that 1 in 5 (around 12.7 million) have been diagnosed with a lung condition in the UK. If you’re over the age of 70, this rises to 1 in 3. [More]
Study provides key insights for effective treatment of individuals with HFpEF

Study provides key insights for effective treatment of individuals with HFpEF

The number of patients hospitalized with HFpEF is now comparable to those with traditional heart failure with a reduced ejection fraction (HFrEF) and is projected to exceed that of HFrEF within the next few years. [More]
UAB receives NIH grants in three perinatal networks to improve maternal and infant health

UAB receives NIH grants in three perinatal networks to improve maternal and infant health

The University of Alabama at Birmingham is the only university to be awarded grants in all three perinatal networks from the Eunice Kennedy Shriver National Institute of Child Health and Human Development to improve maternal and infant health. [More]
European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year. [More]
Circulating angiogenic factor shows PAH biomarker potential

Circulating angiogenic factor shows PAH biomarker potential

Hepatoma-derived growth factor predicts disease severity and survival in patients with pulmonary arterial hypertension, showing some possible clinical advantages over N-terminal pro-brain natriuretic peptide, researchers report. [More]
New blood test could help predict severity of pulmonary arterial hypertension

New blood test could help predict severity of pulmonary arterial hypertension

Johns Hopkins Medicine researchers report that rising blood levels of a protein called hematoma derived growth factor (HDGF) are linked to the increasing severity of pulmonary arterial hypertension, a form of damaging high blood pressure in the lungs. [More]
Potential non-invasive screening biomarker for SSc-PAH

Potential non-invasive screening biomarker for SSc-PAH

Serum asymmetric dimethylarginine may be an effective non-invasive screening biomarker for systemic sclerosis-related pulmonary arterial hypertension, study findings indicate. [More]
Long-term dasatinib findings support first-line use in CML

Long-term dasatinib findings support first-line use in CML

Final DASISION study findings confirm dasatinib to be an effective, long-term treatment for patients with a new diagnosis of chronic phase-chronic myeloid leukaemia. [More]
Right ventricular echocardiography predicts targeted therapy outcome in PAH

Right ventricular echocardiography predicts targeted therapy outcome in PAH

Echocardiography re-assessment of right ventricular function after targeted therapy is sufficient to predict subsequent prognosis in patients with pulmonary arterial hypertension, say researchers. [More]
Reduced RV functional reserve may explain poor SSc-PAH outcomes

Reduced RV functional reserve may explain poor SSc-PAH outcomes

Patients who develop pulmonary arterial hypertension as a consequence of systemic sclerosis have poorer right ventricular functional reserve than those with idiopathic disease, research published in Circulation shows. [More]
Researchers detect vascular matrix stiffening during early stages of pulmonary hypertension

Researchers detect vascular matrix stiffening during early stages of pulmonary hypertension

Pulmonary hypertension is an abnormal elevation of pressure in the pulmonary circulation that results in stress on the heart and remodeling of blood vessels in the lung. [More]
Elevated endothelial progenitor cells may characterise PAH patients

Elevated endothelial progenitor cells may characterise PAH patients

Plasma levels of endothelial progenitor cells are elevated in patients with pulmonary arterial hypertension, say researchers. [More]
Pulmonary hypertension impacts walking ability in SSc patients

Pulmonary hypertension impacts walking ability in SSc patients

The results of a meta-analysis show the adverse impact pulmonary hypertension has on the walking stamina of patients with systemic sclerosis. [More]

More evidence for combination therapy benefits in PAH

Another meta-analysis adds to evidence of increased benefits for patients with pulmonary arterial hypertension who are given combination therapy. [More]
Detailed digital models of human organs could bring substantial benefits to clinical trials

Detailed digital models of human organs could bring substantial benefits to clinical trials

Computer simulations of disease processes and detailed digital models of our organs could provide more accurate monitoring and outcome measurements for clinical trials, according to research being presented in Sheffield today. [More]
Novel gene therapy can treat pulmonary hypertension linked with heart failure

Novel gene therapy can treat pulmonary hypertension linked with heart failure

Scientists have used a novel gene therapy to halt the progression of pulmonary hypertension, a form of high blood pressure in the lung blood vessels that is linked to heart failure, according to a study led by Roger J. Hajjar, MD, Professor of Medicine and Director of the Cardiovascular Research Center at the Icahn School of Medicine at Mount Sinai. [More]
Hydrocortisone drug can also prevent lung damage in premature babies

Hydrocortisone drug can also prevent lung damage in premature babies

Research from Ann & Robert H. Lurie Children's Hospital of Chicago conducted in mice shows the drug hydrocortisone -- a steroid commonly used to treat a variety of inflammatory and allergic conditions -- can also prevent lung damage that often develops in premature babies treated with oxygen. [More]
Advertisement
Advertisement